New funded projects from Joint Center for Computational Oncology integrate predictive digital twins to improve patient outcomes
The University of Texas MD Anderson Cancer Center, the Oden Institute for Computational Engineering and Sciences and the Texas Advanced Computing Center (TACC) at The University of Texas at Austin have announced seed funding for two new cancer research projects as part of the Joint Center for Computational Oncology (JCCO).
Both of this year's projects aim to create advanced predictive models known as 'digital twins,' which build...
First clinical stage covalent Werner helicase inhibitor shows proof-of-concept in Phase 1 trial
Data from this first-in-human trial of VVD-133214 (formerly RO7589831) prompted further clinical development, including ongoing Phase 1b and...
ASTRO: UT MD Anderson highlights advances in radiation oncology
UT MD Anderson faculty will present nearly 70 abstracts at the 2026 ASTRO Annual Meeting
Scientific presentation topics include advances in...
Daraxonrasib demonstrates initial antitumor activity in RAS-mutant lung cancer
Daraxonrasib is a RAS inhibitor from Revolution Medicines that has been approved by the Food & Drug Administration for previously treated pancreatic cancer
This Phase 1/2 trial is the first-in-human study of daraxonrasib in patients with non-small cell lung cancer
RAS mutations are the most common cancer drivers of non-small cell lung cancer, occurring in about 30% of patients
The results of this trial initiated the Phase 3 RASolve...
Immune signals may help explain, predict responses to therapies for difficult-to-treat depression
Treatment-resistant depression occurs when symptoms persist after multiple antidepressant treatments
Rapid-acting antidepressants, such as ketamine...
New study identifies genetic markers that could guide emerging prostate cancer treatments
Ferroptosis is a type of cell death that has emerged as a promising avenue to target cancers that are resistant to current therapies
This study...
AI-guided pathology analysis can help predict immunotherapy response in rare cancers
Study utilized AI tool to measure baseline and dynamic changes in the tumor microenvironment and tumor content as patients started immunotherapy...
Copper-induced cell death activates immune system, may help overcome immunotherapy resistance
Study identifies a new link between immune cells and a copper-induced form of cell death called cuproptosis
Findings suggest a potential strategy...
AI-powered atlas reveals new insights into tertiary lymphoid structures as prognostic and response biomarkers in cancer
New spatial atlas of immune cell structures, called tertiary lymphoid structures (TLSs), reveals how key features vary across...
UT MD Anderson names Albert Koong, M.D., Ph.D., chief scientific officer
The University of Texas MD Anderson Cancer Center today announced that Albert Koong, M.D., Ph.D., an internationally recognized physician-scientist...